Video
Heart Team: The Evolving Role of Kidney Disease in CVD
Author(s):
In the first episode of our monthly series, cardiologists Jorge Plutzky, MD, and Michael Farkouh, MD, interview nephrologist Matthew Weir, MD.
Introducing Heart Team, a new monthly multimedia series from HCPLive.
Heart Team is hosted by Jorge Plutzky, MD, Director of Preventive Cardiology at Harvard Medical School, and Michael Farkouh, MD, Director of the Peter Munk Clinical Trials Unit and Vice Chair of Medicine at the University of Toronto.
On every episode of Heart Team, Plutzky and Farkouh will deliver a deep dive into the unique developments and pertinent stakeholders throughout cardiovascular medicine. The pair will delve into topics on recent news in research, FDA developments, emerging literature, their own case studies, their personal experiences as caregivers and prescribers, and what more is yet to be learned in the rapidly expanding field.
Each episode will additionally feature a guest interview with an expert in a unique focus of cardiovascular care. The interview will additionally become available as a downloadable podcast episode on HCPLive.
Today’s first episode addresses the growing conversation around simultaneously treating the kidney and the heart, featuring Matthew Weir, MD, director of the division of nephrology at the University of Maryland School of Medicine.
Prior to their discussion with Weir, Plutzky and Farkouh review the emergence of cross-implicative therapies in the field, and the role of cardiologists and internists in managing cardiovascular risks in patients with chronic kidney disease. They additionally review relevant data and personal experience with agents including finerenone and dapagliflozin.
